Brandon Folkes
Stock Analyst at H.C. Wainwright
(2.54)
# 3,020
Out of 4,630 analysts
500
Total ratings
43.1%
Success rate
1%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterated: Buy | $60 | $29.47 | +103.60% | 41 | Aug 7, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterated: Buy | $10 | $7.93 | +26.10% | 7 | Aug 7, 2026 | |
| MNKD MannKind | Reiterated: Buy | $10 | $4.11 | +143.31% | 25 | Aug 6, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $26 | $11.56 | +124.91% | 14 | Aug 6, 2026 | |
| RNTX Rein Therapeutics | Reiterated: Buy | $8 | $0.8175 | +878.59% | 8 | Aug 5, 2026 | |
| INDV Indivior Pharmaceuticals | Reiterated: Buy | $48 | $38.82 | +23.65% | 7 | Aug 4, 2026 | |
| OMER Omeros | Reiterated: Buy | $33 | $13.25 | +149.06% | 25 | Aug 3, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $15.35 | $9.46 | +62.26% | 16 | Jul 31, 2026 | |
| PYPD PolyPid | Reiterated: Buy | $13 | $4.84 | +168.60% | 10 | Jul 21, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $21 → $24 | $18.51 | +29.66% | 13 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $0.792 | +1,288.89% | 10 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12.56 | $1.99 | +531.11% | 13 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $121 | $78.25 | +54.63% | 22 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.21 | +217.46% | 15 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $6.65 | +80.45% | 13 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $13.77 | +45.24% | 11 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | $0.532 | +87.97% | 4 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.4908 | +307.50% | 38 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 → $3 | $1.43 | +109.79% | 19 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $1.22 | +555.74% | 14 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $5.30 | +239.62% | 8 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $9.06 | +220.09% | 8 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.65 | +506.06% | 2 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $7.44 | +74.73% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $28.36 | +111.57% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $6.43 | +102.18% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $200 | $3.98 | n/a | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $7.14 | n/a | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $23 → $16 | $4.84 | n/a | 29 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $4 | $2.35 | n/a | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $10 | $0.85 | n/a | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 3 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 2 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 → $33 | $0.0509 | n/a | 18 | Mar 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $15 | $2.33 | n/a | 15 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $262.19 | n/a | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $40 | $0.605 | n/a | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $0.0005 | n/a | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $50 | $0.001 | n/a | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $22 → $32 | $49.17 | n/a | 12 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $25 | $46.43 | n/a | 3 | Nov 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $210 | $256.56 | n/a | 10 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $8 | $0.000001 | n/a | 4 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $34.10 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $12 | $9.60 | n/a | 9 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $33 | $18.61 | n/a | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $30 | $34.29 | n/a | 2 | Sep 12, 2016 |
Collegium Pharmaceutical
Aug 7, 2026
Reiterated: Buy
Price Target: $60
Current: $29.47
Upside: +103.60%
Xeris Biopharma Holdings
Aug 7, 2026
Reiterated: Buy
Price Target: $10
Current: $7.93
Upside: +26.10%
MannKind
Aug 6, 2026
Reiterated: Buy
Price Target: $10
Current: $4.11
Upside: +143.31%
Zevra Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $26
Current: $11.56
Upside: +124.91%
Rein Therapeutics
Aug 5, 2026
Reiterated: Buy
Price Target: $8
Current: $0.8175
Upside: +878.59%
Indivior Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $48
Current: $38.82
Upside: +23.65%
Omeros
Aug 3, 2026
Reiterated: Buy
Price Target: $33
Current: $13.25
Upside: +149.06%
Eupraxia Pharmaceuticals Inc.
Jul 31, 2026
Reiterated: Buy
Price Target: $15.35
Current: $9.46
Upside: +62.26%
PolyPid
Jul 21, 2026
Reiterated: Buy
Price Target: $13
Current: $4.84
Upside: +168.60%
Trevi Therapeutics
Jul 20, 2026
Reiterated: Buy
Price Target: $21 → $24
Current: $18.51
Upside: +29.66%
Jul 16, 2026
Reiterated: Buy
Price Target: $11
Current: $0.792
Upside: +1,288.89%
Jul 14, 2026
Reiterated: Buy
Price Target: $12.56
Current: $1.99
Upside: +531.11%
Jul 13, 2026
Maintained: Buy
Price Target: $121
Current: $78.25
Upside: +54.63%
Jun 25, 2026
Reiterated: Buy
Price Target: $7
Current: $2.21
Upside: +217.46%
Jun 23, 2026
Reiterated: Buy
Price Target: $12
Current: $6.65
Upside: +80.45%
Jun 23, 2026
Reiterated: Buy
Price Target: $20
Current: $13.77
Upside: +45.24%
Jun 18, 2026
Downgraded: Hold
Price Target: $8 → $1
Current: $0.532
Upside: +87.97%
Jun 8, 2026
Maintained: Buy
Price Target: $2
Current: $0.4908
Upside: +307.50%
Jun 5, 2026
Initiated Coverage: Buy
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
May 26, 2026
Maintained: Buy
Price Target: $8
Current: $1.22
Upside: +555.74%
May 26, 2026
Reiterated: Buy
Price Target: $18
Current: $5.30
Upside: +239.62%
May 26, 2026
Maintained: Buy
Price Target: $29
Current: $9.06
Upside: +220.09%
May 20, 2026
Reiterated: Buy
Price Target: $10
Current: $1.65
Upside: +506.06%
May 15, 2026
Reiterated: Buy
Price Target: $13
Current: $7.44
Upside: +74.73%
May 15, 2026
Reiterated: Buy
Price Target: $60
Current: $28.36
Upside: +111.57%
May 14, 2026
Reiterated: Buy
Price Target: $13
Current: $6.43
Upside: +102.18%
Mar 4, 2025
Reiterated: Buy
Price Target: $8 → $200
Current: $3.98
Upside: n/a
Nov 14, 2024
Initiated Coverage: Buy
Price Target: $5
Current: $7.14
Upside: n/a
Aug 22, 2024
Initiated Coverage: Buy
Price Target: $23 → $16
Current: $4.84
Upside: n/a
May 3, 2024
Maintained: Buy
Price Target: $3 → $4
Current: $2.35
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $20 → $10
Current: $0.85
Upside: n/a
Mar 17, 2023
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Mar 17, 2023
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Mar 13, 2023
Maintained: Hold
Price Target: $37 → $33
Current: $0.0509
Upside: n/a
Feb 9, 2023
Maintained: Buy
Price Target: $22 → $15
Current: $2.33
Upside: n/a
Feb 3, 2023
Reiterated: Buy
Price Target: $48
Current: $262.19
Upside: n/a
Nov 22, 2022
Maintained: Buy
Price Target: $22 → $40
Current: $0.605
Upside: n/a
Nov 2, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $0.0005
Upside: n/a
Mar 31, 2022
Maintained: Buy
Price Target: $5 → $50
Current: $0.001
Upside: n/a
Jan 27, 2022
Upgraded: Buy
Price Target: $22 → $32
Current: $49.17
Upside: n/a
Nov 4, 2021
Reiterated: Buy
Price Target: $23 → $25
Current: $46.43
Upside: n/a
Oct 6, 2021
Maintained: Buy
Price Target: $210
Current: $256.56
Upside: n/a
Aug 9, 2021
Maintained: Buy
Price Target: $6 → $8
Current: $0.000001
Upside: n/a
Jun 30, 2021
Initiated Coverage: Buy
Price Target: $45
Current: $34.10
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $18 → $12
Current: $9.60
Upside: n/a
Dec 15, 2020
Reiterated: Buy
Price Target: $25 → $33
Current: $18.61
Upside: n/a
Sep 12, 2016
Reiterated: Buy
Price Target: $34 → $30
Current: $34.29
Upside: n/a